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Irbesartan is an antihypertensive with limited bioavailability and solid lipid nanoparticles (SLN) is one 
of the approaches to improve bioavailability. Solid lipid nanoparticles were prepared using glyceryl 
monostearate by solvent emulsification method followed by probe sonication. Irbesartan loaded SLNs 
were characterized and optimized by parameters like particle size, zeta potential, surface morphology 
entrapment efficiency and in vitro release. The optimized formulation was then further evaluated for 
the pharmacokinetic studies in Wistar rats. Irbesartan-loaded SLN of particle size 523.7 nm and 73.8% 
entrapment efficiency showed good bioavailability in Wistar rats and also showed optimum stability in 
the studies. The SLN prepared using glyceryl monostearate by solvent emulsification method leads to 
improve bioavailability of the drug.
Uniterms: Irbesartan/pharmacokinetics. Irbesartan/preparation. Irbesartan/bioavailability. Glyceryl 
monostearate. Solid lipid nanoparticles/characterization. 
INTRODUCTION
Colloidal systems are the most promising alternative 
drug delivery systems for improving the bioavailability 
and therapeutic availability of the drugs. The colloidal 
systems include micelles, vesicles, liposomes, liquid 
crystals, nanocrystals, nanoparticles, etc. The particle 
size of the mentioned nano-carriers varies from 10 to 800 
nm. Solid lipid nanoparticles (SLN) comprises solid lipid 
core stabilized by a surfactant at interfacial region. The 
solid lipids are used for the preparation of SLN instead 
of liquid lipids (used in case of liposomes) to overcome 
the disadvantages associated with the liquid state and to 
improve physical stability. SLN possesses advantages 
over other colloidal delivery systems of increased physical 
stability, high drug payload and absence of carrier bio-
toxicity. The preparation of SLN can also be extrapolated 
to large scale production. The methods viz., high 
pressure homogenization, solvent evaporation, solvent 
emulsification, ultrasonication etc. are reported to be used 
for the preparation of solid lipid nanoparticles (Mehnert, 
Mader, 2001; Muller, Mader, Gohla, 2000; Uner, 2006).
Irbesartan is an angiotensin II receptor antagonist, 
used for the management of hypertension. The drug is 
practically insoluble in water. It has 90% plasma protein 
binding and 60-70% bioavailability. Therefore, large 
therapeutic doses (75 mg to 300 mg) are required for the 
required effect. Several approaches as solid dispersion 
or polymeric nanoparticles or inclusion complex 
with cyclodextrin have been reported to improve the 
bioavailability of the drug. However, various literature 
suggested solid lipid nanoparticle as an efficient way to 
improve bioavailability of drugs along with improved 
physical stability (Ganapuram et al., 2013; Zhang et al., 
2012; Hirlekar, Kadam, 2009). Thus, the present study 
was carried out with the aim to improve the solubility and 
dissolution profile of irbesartan by preparing its solid lipid 
nanoparticles using the solvent emulsification method. 
The prepared nanoformulation was characterized and 
evaluated for in vitro release and in vivo studies.
MATERIALS AND METHOD
Irbesartan was received as a gift sample from Lupin 
Research Park Ltd, Pune, India. All the chemicals used in 
the study were of analytical grade.
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Method of preparation of solid lipid nanoparticle
The solid lipid nanoparticles (SLNs) were 
prepared by a solvent emulsification method. Glyceryl 
monostearate (GMS) was dissolved in organic phase 
(ethanol) by heating at 70-80°C and 75 mg of irbesartan 
was dissolved by adding in to the solution. The prepared 
solution was added to a hot poloxamer 407 (P407) 
solutions (5°C above melting point of the lipid) under 
stirring using a polytron homogenizer at 15,000 rpm for 
15 minutes. The resultant dispersion was immediately 
sonicated using a probe sonicator at amplitude of 50% 
with the pulse of 4 sec intervals. After probe sonication 
the organic solvents present in the solution was 
evaporated using rotavapour for 2 hours at 80 rpm. The 
prepared SLN samples were freeze dried at -48 °C for 
24 hours to yield dry powder. The amount of irbesartan 
was fixed, i.e., 75 mg. whereas, the amount of GMS and 
P407 was varied. Various batches coded as F1 to F5 and 
P1 to P5 with varying the amount of GMS and P407, 
respectively were prepared (Table I).
Determination of particle size, polydispersity 
index (PDI) and zeta potential
The particle size (PS), polydispersity index and 
zeta potential of the prepared SLN before and after freeze 
drying was measured using Malvern Nano ZS zetasizer. 
All the measurements were performed in triplicate. The 
various batches were evaluated to optimize the SLN for 
further studies.
Drug entrapment efficiency
Entrapment efficiency of the drug in SLNs was 
determined by quantifying the amount of free drug in the 
dispersion medium using below equation
 
10mg of freeze dried irbesartan-loaded SLN was 
dissolved in 5 mL of ethanol. 1ml of the above solution was 
diluted to 10 ml with phosphate buffer pH 7.4 and filtered 
using 0.45 µm membrane filters. The absorbance of the 
filtered solution was recorded by UV spectrophotometer 
at 244 nm (UV-1601PC, Shimadzu, Japan).
In vitro release studies
The in vitro dissolution or release study of the 
optimized freeze dried irbesartan-loaded SLN (F3) was 
carried using USP Type I dissolution apparatus (Basket 
method) at 50 rpm. The equivalent amount of formulation 
F3 was taken containing 75 mg of irbesartan. The test was 
carried out in 900 mL of 0.1 N HCl for the first 2 hours, 
followed by the pH 7.4 phosphate buffer containing 0.25% 
tween 80 solution. The temperature of the dissolution 
medium was maintained at 37 ± 0.5 °C, keeping it in 
thermostatically controlled water. The samples were 
withdrawn at predetermined time intervals, i.e. 0.5, 1, 2, 
2.5, 3, 4, 5, 6, 8, 12, 24 and 48 hours and replaced with fresh 
dissolution media. The drug concentration was determined 
TABLE I - Composition and characterization of the prepared SLNs
Formulation 
Code GMS (%) P407 (%)
Before freeze drying After freeze drying Zeta 
potential 
(mv)
Particle Size 
(nm)±SD PDI
Particle Size 
(nm)±SD PDI
F1 2 1.5 363±9.19 0.263 437.2±9.05 0.386 -19.3
F2 2.5 1.5 380±1.41 0.418 536.8±2.26 0.662 -16.5
F3 3 1.5 523.7±15.6 0.266 629.2±14.7 0.526 -21.5
F4 3.5 1.5 550±14.14 0.354 678±7.77 0.725 -20.0
F5 4 1.5 617.2±1.97 0.241 534±11.31 0.625 -16
P1 3 2 672±2.12 0.450 712±16.26 0.506 -17.6
P2 3 2.5 709.2±1.97 0.243 809±2.12 0.276 -14.3
P3 3 3 836±9.19 0.1913 842.3±4.45 0.243 -13.9
P4 3 3.5 826±3.53 0.812 936.1±5.02 0.386 -19.3
P5 3 4 1129±14.14 1.00 1287±7.07 0.812 -13.3
The particle size is expressed as Mean ± SD.
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by measuring absorbance spectrophotometrically at 244 
nm.
Shape and surface morphology
The morphology of the optimized freeze dried 
irbesartan-loaded SLN F3 was studied by scanning 
electron microscopy (SEM).
Differential scanning calorimetry (DSC) and 
FT‑IR spectroscopy
DSC analysis and FT-IR spectroscopy of the pure 
drug and the optimized freeze dried irbesartan-loaded 
SLN F3 was performed. For DSC, the samples were 
placed in a sealed aluminium pan and heated under N2 
flow (30 mL/min) at a scanning rate of 5 °C/min from 25 
°C to 250 °C. Empty aluminium pan was considered a 
reference. Duplicate determinations were carried out for 
each sample. Infrared spectroscopy was performed using a 
Shimadzu FT-IR 8300 spectrophotometer and the spectra 
were recorded in duplicate for each of the samples at the 
region of 4000 to 400 cm-1.
Pharmacokinetic Studies
Animals
Male Wistar rats weighing 200-250 g were used 
in the study. The pharmacokinetic study protocol was 
approved by the Institutional Animal Ethical Committee, 
Manipal University, Manipal (vide# IAEC/KMC/18/2010-
2011). Three animals were housed in each cage. Animals 
had free access to food and water.
Bio-analytical method
The concentration of irbesartan in the plasma 
samples was estimated by reversed-phase HPLC (HPLC, 
LC–2010 CHT, Shimadzu Corporation, Kyoto, Japan) 
(Erk, 2003). The chromatography was performed using 
column, Licrospher RP C18 (250 × 4.6 mm, 5 µ). The 
mobile phase used was 10 mM phosphate buffer, pH 
3.0:acetonitrile (55:45% v/v). The flow rate was 1 mL/
min. The mobile phase was filtered through 0.45 μm nylon 
filters (Millipore, USA). Samples were injected at 50 μL 
volume and the peaks were recorded at a wavelength 244 
nm. The concentrations were computed and compared.
Oral administration
Animals were randomized into two groups 
comprising three animals in each group. Animal were 
fasted overnight with free access to water. The pure 
irbesartan and the optimized irbesartan-loaded SLN F3 
were administered orally at doses of 10 mg/kg. Four to 
six hundred microlitres of blood was collected using 
heparinized capillaries from retro orbital plexus. The 
time intervals of 0.25, 0.75, 1, 2, 4, 8, 12 and 24 hours 
were prefixed (Davi et al., 2000). The blood samples 
were centrifuged at 10,000 rpm for 5 minutes (Spinwin, 
Tarson, Kolkata). The plasma was separated and stored at 
-80 °C until further analysis. The samples were analysed 
using HPLC.
Extraction of irbesartan from rat plasma
Briefly 95 µL of blank rat plasma was taken in the 
1.5 mL centrifuge tube and 5 µL of irbesartan of varying 
concentrations and 10 µL of internal standard (IS) working 
stock solution (50 µg/mLof telmisartan) was added 
and vortexed for 1 minute. Then 250 µL of extracting 
solvent of methanol was added, vortexed for 10 minutes 
and centrifuged at 10,000 rpm for 5 minutes. The clear 
supernatant was transferred to HPLC vial and 50 µL was 
injected in the HPLC system for analysis.
Pharmacokinetic analysis
The pharmacokinetic parameters such as t1/2β, 
C0, clearance (Cl) and volume of distribution (Vd) 
were determined using non-compartmental analysis, 
PK solution 2.1 software (Summit research Services, 
Montrose, Colorado, USA). Area under the curve (AUC) 
from zero to infinity was computed using the trapezoidal 
method. The terminal elimination rate constant (β) was 
determined from log linear concentration versus time 
plot and eventually, the half life (t1/2β) was calculated 
using formula 0.693/β. The plasma drug concentration of 
irbesartan at time zero (C0) was obtained by extrapolating 
time-plasma concentration profiles (Arumugam et al., 
2009).
Statistical analysis
Statistical analysis was carried out using software, 
SPSS 11.5 package (University of Cambridge, UK). The 
difference in the parameters was analysed by unpaired 
student’s T-test at 95% confidence interval. The difference 
was considered statistically significant at p<0.05.
Stability studies
The optimized freeze dried irbesartan-loaded SLN 
(F3) was evaluated for the accelerated stability studies in 
accordance with the ICH guidelines. India falls into zone 
3 as per the ICH guidelines and the accelerated studies are 
to be carried out at 40 °C ± 2 °C temperatures and 75 ± 5% 
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relative humidity for a period of 45 days. The samples were 
withdrawn at predetermined time periods, i.e. 15, 30 and 45 
days and evaluated for drug content and mean particle size.
RESULTS
Particle size, polydispersity index and zeta 
potential
The particle size and PDI of the prepared batches 
were measured before and after freeze drying. The particle 
size was observed in the range of 360 to 1129 nm with 
zeta potential -13 to -21.5 mV for the prepared batches 
of SLN. It has been observed that an increase in lipid 
content (GMS) does not significantly affect the particle 
size; however, the particle size increased with increasing 
poloxamer 407 concentrations. The particle size was also 
observed to be increased after freeze drying. The particle 
size and zeta potential are depicted in Table I.
Drug entrapment efficiency
The percent entrapment was observed to vary between 
41.2 to 73.8%. The percentage entrapment efficiency was 
observed to increase with the increase in lipid (GMS) 
concentration from 2% to 3% (i.e., formulations batches 
F1 to F3). However, the concentration of lipid beyond 3% 
did not show significant increase in entrapment efficiency. 
The percentage entrapment efficiency was observed to be 
decreased with the increase in concentration of poloxamer 
407 from 1.5% to 4% (i.e., formulations batches P1 to P5) 
(Table II). It has been observed that irbesartan-loaded SLN 
F3 showed higher percent entrapment i.e. 73.8% compared 
to other formulations.
In vitro release studies
In vitro drug release study of the selected SLNs (F1, 
F2, F3, F4, and F5) was carried out. The SLNs exhibited 
biphasic release pattern with initial release in 2 hours in 
0.1N HCl followed by a sustained release for 48 hours. 
Twenty percent of the incorporated amount of drugs was 
found to be released during the first 2 hours, followed by 
a slowed release of 97% of the drug up to 48 hours. The 
irbesartan-loaded SLN F3 showed a better release profile 
of 97.58% by 48 hours. The prolonged release at 48 hours 
can be attributed to slow diffusion of drug from lipid 
matrix. The results of in vitro drug release are depicted 
in Table III.
Selection of the optimized formulation
It was observed that the irbesartan-loaded SLN F3 
showed optimum particle size before and after freeze 
drying, zeta potential, high entrapment efficiency, and 
better release profile among the prepared batches of SLNs. 
Therefore, freeze dried irbesartan-loaded SLN F3 was 
selected for further evaluation of surface morphology and 
in vivo studies.
Release kinetics
The kinetics of drug release was evaluated to 
prove its design and performance. The mechanism and 
kinetics of drug release from SLN was assessed by 
plotting graphs of various kinetic models. The release 
profile of formulation F3 was found to be fitted best with 
Korsmeyer-Peppas model. The release kinetic profiles of 
the optimized formulation (irbesartan-loaded SLN F3) 
such as zero-order, first-order, Higuchi and Korsmeyer-
Peppas are shown in Figure 1.
A high correlation was observed in the Korsmeyer-
Peppas and zero-order plots. The rate constants were 
calculated from the slope of the respected plots (table 
IV). The K value was 0.6257 indicating that the release 
of the drug was controlled by diffusion of an anomalous 
type (drug diffusion in the hydrated matrix and polymer 
relaxation).
Shape and surface morphology
Scanning electron microscopy (SEM) of pure drug 
revealed small particles with slightly spherical shape 
(Figure 2a). In case of irbesartan-loaded SLN F3, the 
particles were observed to be aligned in intimate contact 
TABLE II - Characterization of the prepared SLNs
Formulation Code % EE±SD (n=3)
F1 54.57±3.698
F2 63.1±1.484
F3 73.8±2.121
F4 59.1±2.969
F5 46.05±3.500
P1 69.47±3.160
P2 65.21±2.057
P3 59.86±2.729
P4 44.02±1.400
P5 41.2±2.687
The % entrapment efficiency is expressed as Mean ± SD.
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TABLE III - In vitro release profile of irbesartan from the freeze dried SLNs (F1 to F5)
Sampling Time 
(hour)
% Cumulative Drug Release (CDR) ± SD (n= 3)
F1 F2 F3 F4 F5
0.5 8.58±0.947 9.87±0.909 7.21±2.113 5.91±1.096 5.05±0.565
1 11.23±0.472 15.1±1.904 10.62±0.93 8.91±1.055 8.03±0.748
2 14.75±1.328 34.56±4.148 15.78±0.805 11.39±0.913 11.16±0.590
2.5 19.92±0.570 43.17±2.971 16.57±1.176 11.77±0.918 9.84±3.534
3 21.41±1.050 48.87±1.003 19.80±5.11 12.63±2.911 9.64±4.566
4 24.15±0.677 53.14±1.631 24.20±1.012 17.84±5.827 13.02±3.664
5 30.59±1.588 60.51±0.465 33.15±3.329 21.79±3.444 18.09±4.089
6 40.31±0.767 64.52±1.171 43.51±6.476 31.72±11.99 24.92±6.367
8 40.02±2.395 67.53±2.221 57.69±8.039 50.45±12.74 42.63±11.192
12 41.05±3.520 71.20±1.864 72.92±6.248 64.42±11.03 54.41±5.111
24 58.46±1.437 74.27±4.971 81.96±2.891 80.12±7.668 75.44±4.168
48 61.92±0.776 83.93±3.576 97.58±1.854 90.8±3.609 88.11±3.231
The % CDR is expressed as Mean ± SD.
TABLE IV - Release kinetics of irbesartan-loaded SLN F3
Zero order First order Higuchi model Korsmeyer-Peppas model
R2 K R2 K R2 K R2 K
0.9823 5.366 0.9597 0.1357 0.9496 15.64 0.9828 0.6257
FIGURE 1 - Release profile of irbesartan-loaded SLN F3, (a) zero order, (b) first order, (c) Higuchi model and (d) Korsmeyer-
Peppas model.
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as fiber like structures. All the particles were observed as 
discrete entities, indicated that lyophilisation did not cause 
aggregation of particles (Figure 2b). These particles were 
readily redispersible. SEM analysis also revealed that 
interaction between solid lipid and drug lead to matrix 
structure, which is different from SEM image of pure 
drug. This indicates that drug molecules are completely 
dispersed in the lipid structures leading to formation of 
nanoparticles.
Differential scanning calorimetry and FT‑IR 
spectroscopy
The possible interaction between irbesartan and 
the carrier was studied by FT-IR spectroscopy and DSC. 
IR spectral analysis for drug alone and irbesartan-loaded 
SLN F3 was carried out. The principal IR peaks of pure 
irbesartan and irbesartan-loaded SLN F3 are shown in 
figures 3a and 3b. In case of irbesartan-loaded SLN F3, 
two peaks were missing and other peaks were found 
with reduced intensity compared to pure drug, indicating 
reduced crystallinity of drug in the formulation.
The DSC thermograms of pure irbesartan and 
irbesartan-loaded SLN F3 are shown in figures 4a and 4b. 
Pure irbesartan showed a sharp peak (endotherm) at 181°C 
corresponding to its melting point/transition temperature. 
There was a shift in the melting point of the drug when it 
was formulated into SLN indicating reduced crystallinity 
of drug (Singh et al., 2014).
Pharmacokinetic studies
Irbesartan-loaded SLN F3 showed significant 
enhancement in the systemic exposure than the pure drug 
(Table V). The Cmax of the SLN F3 increased by two folds 
and the Tmax decreased by 5.33 folds as compared to the 
pure drug. The SLN F3 had increased the half-life by 2 
fold than the pure drug. Though the Tmax of SLN F3 was 
achieved within 0.75 hours, the elimination rate constant 
was observed to be significantly decreased, i.e., 15 times 
less than that of pure drug. The clearance of the SLN F3 
was slightly lower, whereas higher apparent volume of 
distribution was observed than the pure drug. The mean 
residence time (MRT) of SLN F3 was observed to be 
increased by 1.48 fold than the pure drug. The relative 
bioavailability of the optimized irebesartan-loaded SLN 
F3 was found to be 148.03%. The plasma concentration 
of irbesartan and irebesartan-loaded SLN F3 is depicted 
in Figure 5.
Stability
The stability studies were carried out at 2-8 ºC and 
25 ºC/ 60% RH for a period of 1 month. The mean particle 
size and drug content of the samples were determined as a 
function of storage time. The effect of storage conditions 
on particle size and entrapment efficiency are depicted 
in table VI. The stability testing after 30 days led to 
the conclusion that not much significant difference was 
observed in the particle size and entrapment efficiency of 
the solid lipid nanoparticles stored for 30 days.
DISCUSSION
Solid lipid nanoparticles of irbesartan were produced 
successfully with the solvent emulsification method 
using glyceryl monostearate in the present study. The 
objective of the formulation design was to enhance 
the solubility, thereby increasing the bioavailability 
FIGURE 2 - SEM of (a) Irbesartan and (b) Irbesartan-loaded 
SLN F3.
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FIGURE 3 - FT-IR spectra of (a) pure drug, Irbesartan and (b) Irbesartan-loaded SLN F3.
of irbesartan. Poloxamer 407 was used to improve the 
stability of the prepared SLNs. Glyceryl monostearate was 
reported to increase solubility of drugs, therefore it was 
chosen for the preparation of solid lipid nanoparticles of 
irbesartan (Luo et al., 2006; Trotta, Debernardi, Caputo, 
2003). The prepared SLN nanodispersion was freeze-
dried after preparation to increase the shelf life of the 
SLNs. (Schwarz, Mehnert, 1997). The prepared SLN 
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formulations were evaluated for various physicochemical, 
in vitro dissolution and in vivo analysis. It was observed 
that the size of the prepared SLN varied by modulating 
lipid content. The prepared SLNs showed the mean 
particle size in the nanometer range and better stability. 
SEM analysis revealed an interaction between solid lipid 
and drug leading to matrix structure. This indicated that 
the drug molecules are completely dispersed in the lipid 
structures leading to formation of nanoparticles. 
GMS was observed to retard the release of irbesartan 
of the drug in pH 7.4 than in 0.1N HCl in in vitro release 
studies as reported earlier that the lipid matrix could retard 
the release of the drug (Witzleb et al., 2012). The release 
of irbesartan from the optimized formulation F3 showed 
best fit to Korsmeyer-Peppas equation. This showed the 
non-fickian mode of irbesartan release from the optimized 
formulation F3. These observations indicated that the drug 
release was not because of water penetration into the matrix, 
which explained the characteristic of a lipid-based system 
and zero order kinetics could be attributed to the release of 
drug by diffusion (Rosiaux et al., 2014; Silva et al., 2012).
The pharmacokinetic studies in rats showed 
significant increase of the relative bioavailability of the 
optimized SLN formulation F3 as compared to pure 
FIGURE 4 - DSC thermograms of (a) pure drug, Irbesartan and (b) Irbesartan-loaded SLN F3.
FIGURE 5 - Plasma concentration profile of irbesartan and 
irbesartan-loaded SLN F3.
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TABLE V - Pharmacokinetic parameters of irbesartan and irbesartan-loaded SLN F3
Parameters Units Irbesartan Irbesartan-loaded  SLN F3
Tmax hr 4.00 ± 0.5 0.75 ± 0.28*
Cmax µg/ml 2.20 ± 0.56 4.19 ± 0.74*
AUC (0-∞) µg.hr/m 15.20 ± 2.67 22.50 ± 5.45
T1/2 hr 4.62 ± 0.85 9.09 ± 1.52*
CL L/hr 0.66 ± 0.12 0.44 ± 0.08
Vd (Apparent) L 4.39 ± 0.95 5.83 ± 1.28
Kel 1/hr 0.15 ± 0.02 0.01 ± 0.005*
MRT hr 6.00 ± 1 8.90 ± 1.56
Relative F % - 148.03 ± 15.42*
The values are expressed as Mean ± SD. * shows significant difference in parameters at p<0.05 as compared to irbesartan.
TABLE VI - Effect of storage on particle size and entrapment efficiency of irbesartan-loaded SLN F3
Storage 
Conditions
Particle size (nm) 
(Mean ± SD)
Entrapment efficiency (%) 
(Mean ± SD)
Initial 15 days 30 days Initial 15 days 30 days
2-8ºC 629.2±14.7 634±10.22 640.5±8.12 73.8±2.12 72.6±1.98 71.19±1.77
25ºC/ 60% RH 629.2±14.7 632±9.41 638.8±5.81 73.8±2.12 71.9±1.75 71.09±1.46
The values are expressed as Mean ± SD.
drug. The Tmax of the formulation F3 was observed to 
be decreased, which could be attributed to the adsorbed 
drug on the surface of the SLN. The clearance of the 
formulation was observed to be decreased resulting in 
sustained action. The possible reason for the reduced 
clearance could be slow release of irbesartan form the 
core of lipid moiety. The stability studies did not show 
any significant difference in size, entrapment efficiency 
and physical appearance of the irbesartan-loaded SLN F3 
indicating its good stability.
CONCLUSION
It can be concluded that the prepared solid lipid 
nanoparticles of irbesartan using GMS and poloxamer 
407 has enhanced bioavailability with sustained release 
of the drug. Further, it can be said that SLN could be 
an alternative approach to other colloidal drug delivery 
systems and tablets for enhancing the bioavailability of 
the drugs and achieving sustained release action.
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